Daybreak The price drop in weight-loss drugs Indian pharma can’t handle
7 snips
Aug 25, 2025 The podcast dives into the explosive growth of GLP-1 weight-loss drugs in India, highlighting the remarkable journey from strict regulations to rapid market entry. It showcases the popularity of medications like Ozempic and Mounjaro, which have transformed the weight-loss landscape. The discussion also touches on the impending price drops and the eager competition among pharmaceutical giants vying for a piece of this booming market. Listeners will gain insights into the industry's challenges and the changing tides of consumer demand.
AI Snips
Chapters
Transcript
Episode notes
Patent Expiry Will Democratize Access
- Semaglutide-driven GLP-1 drugs exploded in demand once weight-loss use became legal in India in 2025.
- Patent expiry in March 2026 could cut prices 85–90%, making treatment affordable to millions.
Big Market, Big Player Rush
- Analysts estimate a $2 billion Indian market by 2030 if even 5% of eligible patients buy at low prices.
- Major Indian firms like Dr. Reddy's and Sun Pharma are already registering to produce semaglutide.
Production Capacity Is The Bottleneck
- India lacks capacity to mass-produce complex peptides like semaglutide at scale and purity today.
- The country still depends heavily on Chinese APIs, with about 70% import reliance in 2025.